Dr. Mike Gendreau Joins Cerephex as Chief Medical Officer October 29 , 201 2 The Cerephex Corporation is pleased to announce that R. Michael Gendreau, MD, PhD, has joined the company as its Chief Medical Officer . In this role, M i ke will lead the company’s clinical development program s involving its proprietary RINCE ® cortical stimulation technology, which is being developed as a treatment for chronic pain , with an initial focus on fibromyalgia . Dr . Gendreau brings to Cerephex over 2 5 years of experience as a Chief Medical Officer in a number of small biotechnology companies , and a track record of achieving regulatory a pprovals for diagnostic, medical devi ce and pharmaceutical products.
Dr. Gendreau has a wealth of experience in therapeutic areas including chronic and acute pain, CNS conditions, and functional somatic syndromes including fibromyalgia. Prior to joining Cerephex, he was a founding member of Cypress Bioscience , a pharmaceutical company that led the development of the drug Savella ® (milnacipran), indicated for the management of fibromyalgia , which gained FDA approval in 2009 . While at Cypress Bioscience, Dr. Gendreau p articipated in virtually all aspects of company operations including strategy, product and technology diligence , as well as development, design, exec ution and management of the company’s clinical programs.
William Mavity, Cerephex’s Pres ident and CEO, commented, “Mike brings a tremendous amount of relevant experience to the Company, and we are fortunate to be able to add his skills and knowledge to t he senior management team. I am very much looking forward to working with him as we endeavor to gain regulatory clearance for a promising technology with the potential to have an immense positive impact on behalf of chronic pain patients. ”
Dr . Gendreau c ommented, “ I’m very pleased to have the opportunity to work with this exciting technology. The potential to improve the pain associated with fibromyalgia without the typical side effects seen with drug therapy represents a significant therapeutic advance in chronic pain treatment. I look forward to co mpleting the necessary studies to gain regulatory approval for the NeuroPoint device and the associated RINCE technology . ”
The addition of Dr . Gendreau adds key medical and operational expertise in a number of strategic areas of that are critical to the success of Cerephex . Among the company’s recent accomplishments , results of a successful multicenter clinical trial evaluat ing the safety and efficacy of the NeuroPoint device as a treatment for fibromyalgia were published in Pain Medicine , the official journal of the American Academy of Pain Medicine ( Pain Med. 2012 Jan;13(1):115 - 24 ) . Follow up data from that study, which suggest a high percentage of treated patients still show symptom improvement nearly four years after therapy, were published in Archives of Physical Medicine and Rehabilitation , the official journal of the American Congress of Rehabilitation Me dicine ( Arch Phys Med Rehabil. 2012 Oct;93 (10):1868 - 71 ) .
Cerephex is a privately held medical technology company focused on developing therapies and diagnostic technologies for chronic centralized pain conditions. For more information about Cerephex, please visit the company’s website at www.cer ephex.com.
Help employers find you! Check out all the jobs and post your resume.
